Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
Crossref DOI link: https://doi.org/10.1007/s11060-016-2094-0
Published Online: 2016-03-02
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Khasraw, Mustafa
Lee, Adrian
McCowatt, Sally
Kerestes, Zoltan
Buyse, Marc E.
Back, Michael
Kichenadasse, Ganessan
Ackland, Stephen
Wheeler, Helen
Funding for this research was provided by:
EMD Serono
Text and Data Mining valid from 2016-03-02